CCEL chairman Portnoy reports stock purchases and option grants
Rhea-AI Filing Summary
Cryo-Cell International (CCEL) director, 10% owner, and Chairman/Co-CEO David Portnoy reported open-market purchases of the company’s common stock. He bought 1,429 shares at $4.00 on 11/17/2025, 640 shares at $4.09 on 11/18/2025, and 1,921 shares at a weighted average price of $4.08 on 11/19/2025.
Following these transactions, he directly beneficially owns 846,540 common shares and also reports additional indirect holdings through various entities and family accounts. He further holds several stock option awards, including grants exercisable at prices ranging from $4.30 to $12.27 per share with expirations between 2027 and 2030 and vesting schedules tied to time and, in one case, the stock reaching $25.00 per share.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,921 | $4.08 | $8K |
| Grant/Award | Common Stock | 640 | $4.09 | $3K |
| Grant/Award | Common Stock | 1,429 | $4.00 | $6K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported is a weighted average price of $4.08. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.
FAQ
What did CCEL insider David Portnoy report on this Form 4?
David Portnoy, a director, 10% owner, and Chairman/Co-CEO of Cryo-Cell International (CCEL), reported recent open-market purchases of the company’s common stock and updated his direct and indirect beneficial ownership, including several existing stock option awards.
What is David Portnoy’s direct ownership in CCEL after these transactions?
After the reported purchases, David Portnoy directly beneficially owns 846,540 shares of Cryo-Cell International common stock.
What indirect CCEL holdings does David Portnoy report?
He reports indirect beneficial ownership of common stock through corporations, a 401(k), an IRA, an LLC, and accounts for family members, reflecting additional exposure beyond his directly held shares.
What stock options in CCEL does David Portnoy hold?
He holds multiple stock option awards on Cryo-Cell common stock with exercise prices such as $7.53, $7.28, $12.27, $4.77, $4.30, $6.47, and $8.08, with expiration dates between 2027 and 2030.
Are any of David Portnoy’s CCEL options subject to performance conditions?
Yes. One option grant vests immediately if the price of Cryo-Cell’s common stock reaches $25.00 per share during its seven-year option term.
How do some of David Portnoy’s CCEL stock options vest over time?
Certain options vest in tranches, for example with portions vesting upon issuance and additional portions vesting on specified future dates such as 12/22/2024, 12/22/2025, 1/2/2025, 1/2/2026, 1/21/2026, and 1/21/2027.